Clinical trials: Allogeneic Stem-Cell Transplant
Epstein-Barr Virus Infection, Cytomegalovirus Infections
TETRAVI Expanded Access Program
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the…
- Conditions
- Epstein-Barr Virus Infection, Cytomegalovirus Infections, Adenovirus Infection, BK Virus Infection
- Trial name
- NCT07104591
- Testing
- HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)
- Sponsor
- Baylor College of Medicine
Acute Graft-versus-host Disease
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of GDC-8264 in participants with acute graft-versus-host disease (aGVHD).
- Trial name
- NCT05673876
- Testing
- GDC-8264
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Genentech, Inc.
Lymphoma Receiving CAR-T Therapy
Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study
This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute…
- Trial name
- FMT (NCT07509450)
- Testing
- Fecal Microbial Transplant Enema
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Depression, Anxiety
Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant
The purpose of this study is to examine the impact that serving as a caregiver for a patient undergoing hematopoietic stem cell transplant has on the caregiver.
- Conditions
- Depression, Anxiety, Fatigue, Distress
- Trial name
- NCT01084694
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northside Hospital, Inc.
SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
The main ailm of this phase I-II study is to evaluate toxicity and efficacy of allogenic mesenchymal stem cell therapy to treat severe systemic sclerosis.
- Conditions
- SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS, ADULT
- Trial name
- MSC (NCT02213705)
- Testing
- INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Ocular Graft-versus-host Disease
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
- Trial name
- NCT03990051
- Testing
- Pro-ocular™ topical gel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Glia, LLC
Hematological Malignancies
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
The present project aims at comparing two nonmyeloablative regimens currently used in 2 major HCT centers in the US for patients with HLA-matched related or unrelated donor: the one from the Seattle group consisting of 2 Gy TBI…
- Trial name
- NCT00603954
- Testing
- Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8 Gy) + ATG
- Where
- 11 sites in Belgium, Netherlands
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Liege
Graft-versus-host Disease, Relapse
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and treatment.
- Trial name
- NCT01941394
- Testing
- Mesenchymal stem cells
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Research Center for Hematology, Russia
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT04464889
- Testing
- MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3
- Where
- Netherlands
- Sponsor
- Medigene AG
Acute Lymphoblastic Leukemia
Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation
Multiple conditioning regimens have been used for the HSCT, some of which include radiotherapy. Total body irradiation (TBI) has demonstrated to be superior to chemotherapy alone in the phase III FORUM trial.
- Trial name
- NCT06209190
- Testing
- total marrow and total lymphoid irradiation
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
AML
Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure
The present trial will establish a prospective sequential Allogeneic Stem Cell Transplantation (allo-SCT) treatment combining both salvage chemotherapy and Reduced Intensity Conditioning (RIC) for primary treatment failure Acute…
- Trial name
- setric (NCT01188174)
- Testing
- Clofarabine
- Where
- 9 sites in France
- Volunteers
- 26 people
- Sponsor
- Nantes University Hospital
Allogeneic Peripheral Blood Stem Cell Transplant
Effects of Stem Cell Transplantation on Bacteria in the Mouth
This study will examine bacteria in patients mouths at different times during stem cell transplantation and recovery. Drugs patients receive as part of the conditioning process for a stem cell transplant increase their risk of…
- Trial name
- NCT00476450
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation, Fatigue
Severe Fatigue in Stem Cell Transplantation
Fatigue is a common symptom during allogeneic-hematopoietic stem cell transplantation (allo-HSCT). However, effects of severe fatigue on pulmonary functions, blood cells, dyspnea, muscle strength, exercise capacity, depression…
- Trial name
- NCT03448471
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- Gazi University
Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic…
- Trial name
- NCT05690971
- Testing
- App, Usual Care
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia
The Efficacy of Allo-HSCT in ND HR-CBF-AML
For newly diagnosed high-relapse-risk core-binding-factor acute myeloid leukemia participants, the investigators aim to perform allogeneic hematopoietic stem cell transplantation after participants finished one cycle of induction…
- Trial name
- NCT06458244
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Chemotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Ruijin Hospital
Leukemia, Chronic Myeloid Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell…
- Conditions
- Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large Cell Lymphoma
- Trial name
- AlloTreo (NCT00598624)
- Testing
- Treosulfan IV
- Where
- 12 sites in Italy
- Volunteers
- 175 people
- Sponsor
- IRCCS San Raffaele
Hematologic Neoplasms
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Allogeneic (Allo) hematopoietic stem cell transplantation (HSCT) is a recognized curative procedure for hematological malignancies.
- Trial name
- HAPLOMUD (NCT02623309)
- Testing
- Allogeneic (Allo) hematopoietic stem cell transplantation
- Where
- 14 sites in France
- Volunteers
- 108 people
- Sponsor
- Institut Paoli-Calmettes
Relapsed Hematologic Malignancy, Multiple Myeloma
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Multiple Myeloma (MM) is a morbid disease which can only be cured with an allogeneic hematopoietic stem cell transplant (HSCT). Approximately 50% of allotransplanted patients will relapse, with a median survival of 5 years.
- Trial name
- NCT03413800
- Testing
- Lenalidomide-Dexamethasone-DLI
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
AML
Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML
The goal of this study is to evaluate the efficacy and safety of a conditioning regimen of Mitoxantrone Hydrochloride Liposome in combination with Bu/Cy (M+Bu/Cy) on acute myeloid leukaemia (AML) patients with…
- Trial name
- NCT06758726
- Testing
- Mitoxantrone Hydrochloride Liposome combined with BU/Cy
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft Versus Host Disease, GVHD
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell…
- Trial name
- NCT00282282
- Testing
- tacrolimus, sirolimus, fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.